Tag: L858R Mutations

Home / L858R Mutations

Categories

Amivantamab-vmjw with carboplatin and pemetrexed is approved by the USFDA for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations

On September 19, 2024, the Food and Drug Administration sanctioned amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) in conjunction with carboplatin and pemetrexed for adult patients diagnosed with ...
l858r-mutations

Scan the code